Acyclovir for Immunocompromised Patients with Herpes Zoster

Ervin Epstein, Jordan B. Glaser, Stephen J. Seligman, Joseph Sack, Uri Martinowitz, Yoram Neuman, Jossi Laks, Daniel Katznelson, Bracha Ramot, Henry H. Balfour, Bonnie Bean, Oscar L. Laskin, Richard F. Ambinder, Joel D. Meyers, James C. Wade, John A. Zaia, Dorothee Aeppli, L. Edward Kirk, Anthony C. Segreti, Ronald E. Keeney

Research output: Contribution to journalLetterpeer-review

4 Scopus citations


To the Editor: The important article by Balfour et al. offers convincing evidence of the value of acyclovir in the management of immunosuppressed patients with herpes zoster (June 16 issue).1 This is a serious and frequently fatal illness. On the other hand, it must not be forgotten that in the usual outpatient practice, where most examples of zoster are encountered, it is not a life-threatening illness. Its importance lies in the discomfort it produces and the possibility of the development of postzoster neuralgia. Therefore, the goals of therapy in this group of patients are different from those considered by Balfour.

Original languageEnglish (US)
Pages (from-to)1254-1255
Number of pages2
JournalNew England Journal of Medicine
Issue number20
StatePublished - Nov 17 1983

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Acyclovir for Immunocompromised Patients with Herpes Zoster'. Together they form a unique fingerprint.

Cite this